The Michael J. Fox Foundation - Translational Pipeline Program | Research Funding

This program will support target validation, pre-clinical and clinical work to foster and accelerate the development of Parkinson’s therapeutics with potential for fundamentally altering disease course or significantly improving management of symptoms.

Funding will support projects that aim to:

• Advance early-stage targets with preliminary rationale for PD pathophysiology and/or symptomology into preclinical therapeutic development by using potent and selective tool compounds to demonstrate therapeutic potential.
   
• Advance through critical preclinical stages the identification, validation, or development of novel approaches and/or new treatments or interventions with potential for significant impact for people with Parkinson’s.
   
• Repurpose or reposition approved or clinically safe therapies from other disease indications.
   
• Progress promising interventions into initial Phase I trials to assess pharmacokinetic/pharmacodynamic and early safety/tolerability.

• U.S. and non-U.S. biotechnology/pharmaceutical companies, or other publicly or privately held for-profit entities; and
   
• U.S. and non-U.S. public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments and eligible agencies of the federal government.
   
• Post-doctoral fellows are not eligible to apply as Principal Investigators or Co-Principal Investigators

• More information about the program is available here
• The application portal can be found here
• For any other questions, please contact the Research Office